News | May 12, 2022
Suven Pharmaceuticals - CDMO core growth intact; formulations to pick up
Anand Rathi maintains long-term guidance of 10-15% revenue growth and 40% EBITDA margins
Anand Rathi maintains long-term guidance of 10-15% revenue growth and 40% EBITDA margins
With launches, continuing momentum in India, other branded markets and a pick-up in the US, Ajanta would deliver 12% revenue/PAT growth each over FY22-24
The company also raised Rs 270 crore investment from Temasek in 2019
Company's net income rose by 57.5 percent to 3.291 billion euros in Q1
Omega plans to further strengthen its capabilities, deepen domain expertise and build new solutions
Myovant to receive an upfront payment of US $50 million, is eligible to receive commercial launch, sales-based and other milestones totaling up to US $90.5 million
Glenmark's current portfolio consists of 174 products authorized for distribution in the U.S. marketplace and 48 ANDA's pending approval with the USFDA
Lupin recognized the need to digitize more applications, improve scalability, decrease risk of security breaches and eliminate critical data loss
Ahead of International Thalassemia Day on 8th May, medical professionals and representatives of patient bodies participated in a virtual discussion on the current situation of Thalassemia management in India
Novel approach driven by GN Corp Japan with potentials in neurological illnesses
Subscribe To Our Newsletter & Stay Updated
